Canada Continues Mpox Vaccinations

The Public Health Agency of Canada (PHAC) today issued a statement offering an update on the ongoing response to the Mpox outbreak.

On February 9, 2023, the World Health Organization (WHO) Director-General declared that Mpox remained a Public Health Emergency of International Concern.

This initial declaration was issued on July 23, 2022.

On February 14, 2023, the WHO noted a sustained decline in Mpox cases globally, with the majority of cases being reported from the Regions of the Americas, with 200-250 cases per week,

And about 4% of Mpox cases occurred in women.

Since the beginning of the Mpox outbreak, the Government of Canada has taken action to protect the health and safety of Canadians.

The ongoing management of Mpox relies on continued vigilance, re-emergence of cases, various public health measures, and vaccination.

Mpox vaccines will continue to be available in Canadian provinces and territories for those at higher risk, including second doses of Imvamune®.

Bavarian Nordic's MVA-BN vaccine is approved by the U.S. Food and Drug Administration for smallpox and Mpox under the JYNNEOS® brand.

Since May 2022, the Government of Canada has deployed over 145,000 doses of vaccine.

Mpox information can be found on the Government of Canada's Mpox: For health professionals website. Other outbreak news is posted at Mpox Today.